Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.

[1]  J. Saarinen,et al.  Radiotherapy treatment modification for prostate cancer patients based on PSMA-PET/CT , 2022, Radiation oncology.

[2]  M. Oderda,et al.  Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  S. Fanti,et al.  Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence. , 2021, European urology oncology.

[4]  O. de Cobelli,et al.  Prostate-specific Membrane Antigen Positron Emission Tomography, Not Conventional Imaging, Should Be Performed for Primary Staging of High-risk Prostate Cancer , 2021, European urology open science.

[5]  M. Cooperberg,et al.  Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. , 2021, JAMA oncology.

[6]  H. Woo,et al.  The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. , 2021, European urology.

[7]  M. Graefen,et al.  PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after radical prostatectomy. , 2021, Urologic oncology.

[8]  R. V. D. van den Bergh,et al.  Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time? , 2021, Frontiers in Surgery.

[9]  S. Fanti,et al.  Diagnostic Performance and Clinical Impact of 68Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study) , 2021, The Journal of Nuclear Medicine.

[10]  C. Stief,et al.  Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer , 2021, Radiation oncology.

[11]  M. Beer,et al.  Changes of Radiation Treatment Concept Based on 68Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy , 2021, Frontiers in Oncology.

[12]  P. Carroll,et al.  A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY) , 2021, The Journal of urology.

[13]  Steve Y. Cho,et al.  Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study , 2021, Clinical Cancer Research.

[14]  U. Haberkorn,et al.  E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  A. Kishan,et al.  Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. , 2020, European urology focus.

[16]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[17]  Daniela A. Ferraro,et al.  Improved oncological outcome after radical prostatectomy in patients staged with 68Ga-PSMA-11 PET: a single-center retrospective cohort comparison , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  V. Khoo,et al.  Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. , 2020, European urology oncology.

[19]  K. D. Sørensen,et al.  68Ga-PSMA PET/CT for primary NM staging of high-risk prostate cancer. , 2020, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  P. Carroll,et al.  Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial , 2020, The Journal of Nuclear Medicine.

[21]  A. Zitella,et al.  68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Jie Gao,et al.  Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer , 2020, Translational andrology and urology.

[23]  N. Lawrentschuk,et al.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.

[24]  H. Zacho,et al.  PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review , 2020, Cancer Imaging.

[25]  P. Dasgupta,et al.  The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  H. Zacho,et al.  Reporting and handling of equivocal imaging findings in diagnostic studies of bone metastasis in prostate cancer , 2019, Acta radiologica.

[27]  R. V. D. van den Bergh,et al.  Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. , 2019, European urology.

[28]  I. Burger,et al.  Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer. , 2019, Radiology.

[29]  S. Fanti,et al.  Prediction nomogram for 68Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  P. Carroll,et al.  Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.

[31]  B. Delahunt,et al.  Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology , 2019, The Journal of urology.

[32]  D. Elashoff,et al.  Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] , 2019, BMC Cancer.

[33]  Minsong Cao,et al.  Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer , 2018, The Journal of Nuclear Medicine.

[34]  S. Fanti,et al.  68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[35]  M. Roscigno,et al.  Difference in Frequency and Distribution of Nodal Metastases Between Intermediate and High Risk Prostate Cancer Patients: Results of a Superextended Pelvic Lymph Node Dissection , 2018, Front. Surg..

[36]  T. Helbich,et al.  PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact , 2018, Clinical Cancer Research.

[37]  S. Fanti,et al.  68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[38]  V. Patel,et al.  The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. , 2018, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[39]  C. Stief,et al.  Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy , 2018, Radiation oncology.

[40]  A. Kishan,et al.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning , 2017, The Journal of Nuclear Medicine.

[41]  Johannes B Reitsma,et al.  Evidence of bias and variation in diagnostic accuracy studies , 2006, Canadian Medical Association Journal.